As of Q3'26 (2025-11-01), MRVL reported R&D Expenses of USD 513M and SG&A Expenses of USD 190M. This marks the highest R&D spending in the period shown, while SG&A expenses remain relatively stable compared to previous quarters. From Q4'23 (2023-01-28) to Q3'26 (2025-11-01), R&D Expenses have demonstrated a steady upward trend, rising from USD 443M to USD 513M, with only minor fluctuations. In contrast, SG&A Expenses have remained comparatively flat, fluctuating within a narrow range around USD 190M–213M, and showing a slight overall decline. This pattern indicates MRVL's increasing investment in research and development while maintaining disciplined control over administrative and selling costs throughout the observed quarters.